Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

250 ML sipuleucel-T 200000 CELLS/ML Injection

Known as: SIPULEUCEL-T/LR SUSP INJ 250ML, SIPULEUCEL-T/LACTATED RINGERS INJ,SUSP,250ML [VA Product], sipuleucel-T 50,000,000 CELLS per 250 ML Injection 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
BACKGROUND Sipuleucel-T is an autologous cellular immunotherapy approved by the US Food and Drug Administration for the treatment… Expand
Review
2012
Review
2012
  • S. Simoens
  • Human vaccines & immunotherapeutics
  • 2012
  • Corpus ID: 23643231
Sipuleucel-T, a new autologous active cellular immunotherapy, is indicated for metastatic castration-resistant prostate cancer… Expand
Review
2012
Review
2012
ZusammenfassungInnerhalb der letzten zwei Jahre hat die Therapie des kastrationsrefraktären Prostatakarzinoms (CRPC) große… Expand
2011
2011
  • J. Armstrong
  • The New England journal of medicine
  • 2011
  • Corpus ID: 205107359
The recent approval by the Food and Drug Administration of Makena, a new version of progesterone 17 alpha-hydroxyprogesterone… Expand
Highly Cited
2008
Highly Cited
2008
There is no single universally accepted hallmark of antigen presenting cell (APC) activation. Instead a variety of methods are… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1